Classic cheap drugs are expected to usher in "freshmen"

Yesterday, the National Health and Family Planning Commission, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Finance, the Ministry of Human Resources and Social Security, the Ministry of Commerce, the Food and Drug Administration, and the Department of Traditional Chinese Medicine jointly convened a special meeting to publicize the State Council’s Medical Reform Leading Group. The "Opinions on the Supply and Maintenance of Commonly Used Low-priced Drugs" (hereinafter referred to as "opinions") was studied and adopted.

This policy is expected to be the most effective way to solve the disappearance of classic cheap drugs in the market. Prior to this, the problem of shortage of medicines became more and more serious. The protamine required for heart surgery, methimazole for the treatment of hyperthyroidism, and ketamine for anesthesia all appeared to be in varying degrees of scarcity, and individual medicines even experienced the phenomenon of “a drug is difficult to obtain”. The State Council also Has repeatedly made instructions on this.

The reporter noted that the "Opinions" announced yesterday confirmed the protection of commonly used low-cost drugs, including a number of classic old drugs, from improving price management, improving procurement methods, establishing shortage drug reserves, and increasing policy support. Policy measures for the production and supply of priced drugs.

“In fact, a closer look will reveal that the core drug catalog and pricing have not been announced this time because there are still differences.” Yesterday, a veteran who was close to the policy development layer revealed in an interview.

The above-mentioned sources told reporters that the NDRC had already identified 890 medicines in the list of low-priced medicines last year. Due to the consistent selection principles of low-cost, safety, and clinical use, a considerable portion of essential medicines are included in the list of low-priced medicines at the same time. .

“But this means that once the list of low-priced medicines starts to run, online bidding procurement according to the existing methods will conflict with the existing local control of the basic medicines list and the bidding procurement agencies’ operating mechanism. This is also the directory to date. There is no important reason for the announcement," said the above person.

At another core issue, prices are even more hazy.

The "Opinions" announced yesterday announced for the first time that for drugs included in the national list of low-priced drugs, the maximum retail price limit for each specific product was abolished, allowing producers and operators to comply with drug production costs and market supply and demand within the average daily fee standard). Conditions are self-developed or adjusted for retail prices to ensure reasonable profits. In accordance with the average daily cost standard, localities determine the list of low-priced drugs within the pricing range of the province (region, city).

“There has been news before that the average daily cost of Chinese patent medicines is no more than 5 yuan, and the daily average cost of chemical medicines is no more than 3 yuan. Although there is no final announcement today (15th), the disparity should not be too great.” The reporter revealed.

At yesterday's meeting, Song Dacai, Director of Price Division of the Price Division of the National Development and Reform Commission, who was in charge of price, explained the calculation method with an example of “average daily price of 3 yuan” when explaining price issues.

"If the average daily cost standard is controlled at 3 yuan, the company's final price will not exceed the upper limit of 3 yuan per day for the average price, and the average retail price will be used as the average retail price, such as twice or three times a day. The total cost of the calculation of the total cost of the last day does not exceed 3 yuan.” Song Dacai said so at the meeting.

The impact of this approach on business may also be the first to appear.

According to the idea already announced by the National Development and Reform Commission, after the drugs that meet the daily average cost standard are included in the list of low-priced drugs, the original retail price will be automatically cancelled. The company can adjust the real-time changes in the supply and demand of the market according to the changes in the cost. price.

For changes in costs or changes in usage and usage that lead to daily average cost breaks through low-price drug control standards, the list of low-priced drugs should be withdrawn and the maximum retail guidance price should be re-established. The pilot countries that use small quantities of drugs and have a short supply of the market have fixed-point production and uniform pricing.

Due to the fact that the catalog and prices of the next-to-next market of the enterprise have not yet been announced, many companies in the interview yesterday stated that they are still cautiously optimistic about the policy and need to wait for more details to be issued to evaluate the impact on the company.

Li Hong, general manager assistant of the Guangyao Pharmaceutical Group, told reporters yesterday that the low-cost medicines were subject to inventory management and dynamic adjustments, and that companies were pricing themselves based on factors such as market and cost within daily expenses. This not only changed the original maximum retail price. The "ceiling" pricing model will also greatly increase the company's production enthusiasm.

Li Hong cited Guanghan Pharmaceutical Group as an example. If according to previous market rumors, the cost of taking Chinese patent medicines does not exceed 5 yuan per day, and the daily cost of chemical medicines does not exceed 3 yuan, the main selling varieties of Guangyao Pharmaceutical Group are all lower prices. Drugs, many varieties of government pricing have not been adjusted for many years, resulting in nearly 50% of low-priced drugs can not be produced. Under the Baiyun Mountain and Huang Banlangen, compound Danshen tablets and other products, due to rising prices of medicinal herbs, labor, etc., the ex-factory price of these products is almost close to the highest retail price, the price of the Group's drugs such as Baoji Pills has not been adjusted for almost 10 years, almost Sell ​​at a loss. If low-priced drugs are subject to list management, they will have a certain degree of autonomy in prices, and they will have a certain amount of room for self-adjustment in the prices of their products. The company's enthusiasm for production will be greatly enhanced, and some cheap drug markets will be restored.

Yesterday, the eight departments did not give a clear timetable for the list of low-price medicines and prices that attracted much attention. However, the Development and Reform Commission said at the meeting that there will be no great suspense during the year and "the sooner the better."